Q1 Earnings Estimate for CMPS Issued By HC Wainwright

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) – HC Wainwright issued their Q1 2026 EPS estimates for COMPASS Pathways in a note issued to investors on Tuesday, July 15th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.41) EPS and Q4 2026 earnings at ($0.43) EPS.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.03.

Several other equities analysts have also issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $12.00 price target on shares of COMPASS Pathways in a report on Tuesday, May 27th. Evercore ISI reaffirmed an “in-line” rating and issued a $6.00 price target (down from $11.00) on shares of COMPASS Pathways in a report on Monday, June 23rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, COMPASS Pathways presently has an average rating of “Moderate Buy” and an average price target of $17.00.

COMPASS Pathways Price Performance

NASDAQ CMPS opened at $3.56 on Wednesday. The firm’s fifty day simple moving average is $3.94 and its two-hundred day simple moving average is $3.77. The company has a current ratio of 10.18, a quick ratio of 10.18 and a debt-to-equity ratio of 0.11. COMPASS Pathways has a 12-month low of $2.25 and a 12-month high of $8.54. The firm has a market capitalization of $333.07 million, a P/E ratio of -1.79 and a beta of 2.12.

Institutional Investors Weigh In On COMPASS Pathways

Large investors have recently made changes to their positions in the stock. Cerity Partners LLC purchased a new stake in shares of COMPASS Pathways during the first quarter valued at $29,000. GAMMA Investing LLC grew its holdings in shares of COMPASS Pathways by 93.6% during the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock valued at $30,000 after buying an additional 5,003 shares during the last quarter. Wealthfront Advisers LLC purchased a new stake in shares of COMPASS Pathways during the fourth quarter valued at $43,000. Ethos Financial Group LLC purchased a new stake in shares of COMPASS Pathways during the first quarter valued at $35,000. Finally, Simplify Asset Management Inc. purchased a new stake in shares of COMPASS Pathways during the fourth quarter valued at $54,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.